Bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension

Drugs and Aging

Volumn 26, Issue 12, 2009, Pages 1049-1071

  Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; DORZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN; TIMOLOL; TRAVOPROST;

AQUEOUS HUMOR OUTFLOW; AREA UNDER THE CURVE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; COST BENEFIT ANALYSIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE BURN; EYE PAIN; EYELASH PIGMENTATION; EYELID PIGMENTATION; FOREIGN BODY SENSATION; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; MAXIMUM PLASMA CONCENTRATION; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PERORBITAL PIGMENTATION; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW; TRABECULAR MESHWORK; VISUAL DISORDER;

AMIDES; AQUEOUS HUMOR; CLOPROSTENOL; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION;

EID: 70849130442     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11203210-000000000-00000     Document Type: Review

References (103)

1. Kwon YH, Fingert JH, Kuehn MH, et al. Primary openangle glaucoma. N Engl J Med 2009 Mar 12; 360 (11): 1113-1124
2. National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and management of open-angle glaucoma and ocular hypertension [online]. Available from URL: Http:// www.nice.org.uk/nicemedia/pdf/CG85FullGuideline.pdf [Accessed 2009 Aug 24]
3. McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care 2008 Feb; 14 (1 Suppl.): S20-7 (Pubitemid 351341925)
4. Geringer CC, Imami NR. Medical management of glaucoma. Int Ophthalmol Clin 2008 Fall; 48 (4): 115-141
5. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Editrice Dogma, 2009
6. American Academy of Ophthalmology. Preferred practice pattern: Primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2005
7. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004 Sep; 111 (9): 1627-1635
8. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000 Apr; 9 (2): 134-142
9. Burk RM, Woodward DF. A historical perspective and recent advances in prostamide research and therapeutics. Curr Opin Drug Discov Devel 2007 Jul; 10 (4): 413-421
10. Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf 2008 Nov; 7 (6): 801-808
11. Easthope SE, Perry CM. Topical bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 19 (3): 231-248
12. Plosker GL, Keam SJ. Bimatoprost: A pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 2006; 24 (3): 297-314
13. Perry CM, McGavin JK, Culy CR, et al. Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging 2003; 20 (8): 597-630
14. Waugh J, Jarvis B. Travoprost. Drugs Aging 2002; 19 (6): 465-71; discussion 472-473
15. European Medicines Agency. Lumigan®: Summary of product characteristics [online]. Available from URL: Http:// www.emea.europa.eu/ humandocs/PDFs/EPAR/lumigan/ H-391-PI-en.pdf [Accessed 2009 Jul 23]
16. Allergan Inc. Lumigan® (bimatoprost ophthalmic solution) 0.03%: US prescribing information [online]. Available from URL: Http://www.lumigan.com/ prescribing-information.aspx [Accessed 2009 Jul 23]
17. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S337-45
18. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008 Nov; 53 Suppl. 1: S107-20
19. Brubaker RF. Mechanism of action of bimatoprost (Lumigan®). Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S347-51
20. Paolera MD, Kasahara N, Umbelino CC, et al. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study. BMC Ophthalmol 2008 Jun 11; 8: 11
21. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008 Feb; 153 (3): 410-419
22. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 2008 Jul; 154 (5): 1079-1093
23. Ota T, Aihara M, Narumiya S, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005 Nov; 46 (11): 4159-4163
24. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001 Dec 7; 432 (2-3): 211-213
25. Davies SS, Ju WK, Neufeld AH, et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther 2003 Feb; 19 (1): 45-54
26. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002 Aug; 47 Suppl. 1: S34-40
27. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: Similarities and differences. Surv Ophthalmol 2008 Nov; 53 Suppl. 1: S69-84
28. Camras CB, Toris CB, Sjoquist S, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 2004; 111 (12): 2193-2198
29. Cantor LB, Hoop J, Wudunn D, et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol 2007 May; 91 (5): 629-632
30. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects; acrossover study. Ophthalmology 2008 May; 115 (5): 790-5.e4
31. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001 Jan; 131 (1): 19-24
32. Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004 Sep; 111 (9): 1658-1662
33. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005 Feb; 112 (2): 262-266
34. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006 Feb; 113 (2): 239-246
35. Walters TR, DuBiner HB, Carpenter SP, et al. 24-Hour IOP control with once-daily bimatoprost, timolol gelforming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004 Mar; 49 Suppl. 1: S26-35
36. Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology 2007 Dec; 114 (12): 2244-2251
37. Frenkel RE, Frenkel M, Toler A. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 2007; 7: 16
38. Frenkel RE, Noecker RJ, Craven ER. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%. Curr Med Res Opin 2008 Apr; 24 (4): 919-923
39. Zeitz O, Matthiessen ET, Reuss J. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: A randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmology 2005; 5 (1): 6
40. Akarsu C, Yilmaz S, Taner P, et al. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol 2004 Oct; 242 (10): 814-818 (Pubitemid 39485530)
41. Alagoz G, Gurel K, Bayer A, et al. A comparative study of bimatoprost and travoprost: Effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008; 222 (2): 88-95
42. Sen E, Nalcacioglu P, Yazici A, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 2008 Aug; 17 (5): 398-402
43. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial. Arch Ophthalmol 2005 Feb; 123 (2): 186-192
44. Arcieri ES, Pierre Filho PT, Wakamatsu TH, et al. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 2008 Feb; 22 (2): 179-183
45. Hatanaka M, Vessani RM, Elias IR, et al. The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 2009 Feb; 25 (1): 51-53
46. Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci 2007 Aug; 48 (8): 3677-3682
47. Yeom HY, Hong S, Kim SS, et al. Influence of topical bimatoprost on macular thickness and volume in glaucoma patients with phakic eyes. Can J Ophthalmol 2008 Oct; 43 (5): 563-566
48. Kapur R, Osmanovic S, Toyran S, et al. Bimatoprost-induced periocular skin hyperpigmentation: Histopathological study. Arch Ophthalmol 2005 Nov; 123 (11): 1541-1546
49. Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normaltension glaucoma. Br J Ophthalmol 2008 Sep; 92 (9): 1227-1231
50. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 2008 Jan 28; 17 (1): 36-39
51. Ozturk F, Ermis SS, Inan UU. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: A 6-month study. Acta Ophthalmol Scand 2007 Feb; 85 (1): 80-83
52. Sharpe ED, Williams RD, Stewart JA, et al. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J Ocul Pharmacol Ther 2008 Aug; 24 (4): 408-413
53. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol 2005 May-Jun 30; 15 (3): 336-342
54. Williams RD, Cohen JS, Gross RL, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: Year 4. Br J Ophthalmol 2008 Oct; 92 (10): 1387-1392
55. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001 Jun; 108 (6): 1023-31; discussion 1032
56. Whitcup SM, Cantor LB, VanDenburgh AM, et al. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 2003 Jan; 87 (1): 57-62
57. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003 Dec; 110 (12): 2362-2368
58. Cantor LB, Hoop J, Morgan L, et al. Intraocular pressurelowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006 Nov; 90 (11): 1370-1373
59. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001 May-Jun 30; 18 (3): 110-121
60. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure- lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003 Jan; 135 (1): 55-63
61. Bacharach J, Schenker HI, Caprioli J, et al. Masked, randomized, parallel comparison of IOP-lowering efficacy after switching to bimatoprost 0.03% vs continuing with latanoprost 0.005% [abstract no. 36 plus poster]. American Glaucoma Society 19th Annual Meeting; 2009 Mar 5-8; San Diego (CA)
62. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003 May; 135 (5): 688-703
63. Noecker RJ, Earl ML, Mundorf TK, et al. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin 2006 Nov; 22 (11): 2175-2180
64. Kammer JA, Katzman B, Ackerman SL, et al. Efficacy and tolerability of bimatoprost versus travoprost in patients previously treated with latanoprost: A 3-month, randomized, masked-evaluator, multicentre study. Br J Ophthalmol. Epub 2009 Sep 1
65. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol 2004 Sep; 242 (9): 767-770
66. Cohen JS, Gross RL, Cheetham JK, et al. Two-year double- masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004 Mar; 49 Suppl. 1: S45-52
67. Higginbotham EJ, Schuman JS, Goldberg I, et al. Oneyear, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002 Oct; 120 (10): 1286-1293
68. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Bimatoprost Study Group. Surv Ophthalmol 2001 May; 45 (6 Suppl. 4): S361-8
69. Simmons ST, Bernstein P, Hollander DA. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Am J Ophthalmol 2008 Sep; 146 (3): 473-477
70. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: Estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006; 24 (3): 251-264
71. Fiscella R, Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging 2006; 23 (1): 39-47
72. Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004 Mar; 49 Suppl. 1: S36-44
73. Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients: A European perspective. Int J Clin Pract 2005 Sep; 59 (9): 1011-1016
74. Holmstrom S, Buchholz P, Walt J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006 May; 22 (5): 897-905
75. Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005 Nov; 21 (11): 1875-1883
76. Whitson JT, Trattler WB, Matossian C, et al. Ocular surface tolerability of prostaglandin analogues (PGAs) in patients with glaucoma or ocular hypertension [abstract no. 34 plus poster]. American Glaucoma Society 19th Annual Meeting; 2009 Mar 5-8; San Diego (CA)
77. Sharpe ED, Reynolds AC, Skuta GL, et al. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res 2007 Dec; 32 (12): 1037-1043
78. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004 Nov; 82 (11): 844-851
79. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002 Oct; 120 (10): 1268-1279
80. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 Jun; 120 (6): 701-13; discussion 829-830
81. Lichter PR, Musch DC, Medzihradsky F, et al. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthalmol 1989 Jan 15; 107 (1): 11-17
82. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998 Oct; 126 (4): 487-497
83. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2001; 130: 429-440
84. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126 (4): 498-505
85. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008Aug; 126 (8): 1030-1036
86. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002 Nov; 11 (11 Suppl.): 16-24
87. Webers CAB, Beckers HJM, Nuijts RMMA, et al. Pharmacological management of primary open-angle glaucoma: Second-line options and beyond. Drugs Aging 2008; 25 (9): 729-759
88. Curran MP, Orman JS. Bimatoprost/timolol: A review of its use in glaucoma and ocular hypertension. Drugs Aging 2009; 26 (2): 169-184
89. Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging 2006; 23 (7): 587-97; discussion 598-599
90. Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 2007 May; 12 (2): 313-327
91. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005 Jun; 112 (6): 953-961
92. Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009 Mar 14; 25 (2): 145-152
93. Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: Population-based study using pharmacy claims data. Clin Experiment Ophthalmol 2007 Sep 31; 35 (7): 602-611
94. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: A meta-analysis. Clin Ophthalmol 2009; 3: 447-456
95. Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007 Mar; 23 (3): 601-608
96. Li N, Chen XM, Zhou Y, et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: Meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 2006 Nov; 34 (8): 755-64
97. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 2005 Jul; 112 (7): 1177-1185
98. How AC, Kumar RS, Chen YM, et al. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol 2009 Jun; 93 (6): 782-786
99. Agarwal HC, Gupta V, Sihota R. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. J Ocul Pharmacol Ther 2003 Apr; 19 (2): 105-112
100. Dirks MS, Noecker RJ, Earl M, et al. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther 2006; 23 (3): 385-394
101. Chen MJ, Cheng CY, Chen YC, et al. Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther 2006 Jun; 22 (3): 188-193
102. Stewart WC, Stewart JA, Jenkins JN, et al. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J Glaucoma 2003 Dec; 12 (6): 475-479
103. Pfzier Inc. Xalatan- latanoprost ophthalmic solution: US prescribing information [online]. Available from URL: Http://www.pfizer.com/files/products/ uspi-xalatan.pdf [Accessed 2009 Aug 26]